Short term there has been pain in seeing the sp decline and cautious optimism in seeing the trials show promising results. I know nothing is a lock but using previous results pre-clinical and clinical can lead one to deduce our chances of a successful indication for one if not multiple drugs is good. It will definitely hurt if P results are not good but B will likely rise us from the ashes. The combined anti-inflammory anti-infectious properties of this drug are ideal for treating so many disease conditions and screaming for a BP to step in and explore.